Journal article

Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models

The phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest efficacy of the vaccine against Plasmodium falciparum malaria, but was not powered to assess mortality endpoints. Impact projections and cost-effectiveness estimates for longer timeframes than the trial follow-up and across a range of settings are needed to inform policy recommendations. We aimed to assess the public health impact and cost-effectiveness of routine use of the RTS,S/AS01 vaccine in African settings.

 

Languages

  • English

Publication year

2016

Journal

The Lancet

Volume

10016

Type

Journal article

Categories

  • Vaccines & delivery devices

Diseases

  • Malaria

Tags

  • New vaccine introduction

Added by: Moderator

Added on: 2016-01-25 05:47:49

Hits: 1611